These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36929625)

  • 21. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 viral load in nasopharyngeal swabs in the emergency department does not predict COVID-19 severity and mortality.
    Le Borgne P; Solis M; Severac F; Merdji H; Ruch Y; Alamé Intern K; Bayle E; Hansmann Y; Bilbault P; Fafi-Kremer S; Meziani F;
    Acad Emerg Med; 2021 Mar; 28(3):306-313. PubMed ID: 33481307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19.
    ; Rogers AJ; Wentworth D; Phillips A; Shaw-Saliba K; Dewar RL; Aggarwal NR; Babiker AG; Chang W; Dharan NJ; Davey VJ; Higgs ES; Gerry N; Ginde AA; Hayanga JWA; Highbarger H; Highbarger JL; Jain MK; Kan V; Kim K; Lallemand P; Leshnower BG; Lutaakome JK; Matthews G; Mourad A; Mylonakis E; Natarajan V; Padilla ML; Pandit LM; Paredes R; Pett S; Ramachandruni S; Rehman MT; Sherman BT; Files DC; Brown SM; Matthay MA; Thompson BT; Neaton JD; Lane HC; Lundgren JD
    Ann Intern Med; 2022 Oct; 175(10):1401-1410. PubMed ID: 36037469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of viral load and antibody response in relation to COVID-19 severity.
    Wang Y; Zhang L; Sang L; Ye F; Ruan S; Zhong B; Song T; Alshukairi AN; Chen R; Zhang Z; Gan M; Zhu A; Huang Y; Luo L; Mok CKP; Al Gethamy MM; Tan H; Li Z; Huang X; Li F; Sun J; Zhang Y; Wen L; Li Y; Chen Z; Zhuang Z; Zhuo J; Chen C; Kuang L; Wang J; Lv H; Jiang Y; Li M; Lin Y; Deng Y; Tang L; Liang J; Huang J; Perlman S; Zhong N; Zhao J; Malik Peiris JS; Li Y; Zhao J
    J Clin Invest; 2020 Oct; 130(10):5235-5244. PubMed ID: 32634129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Viral Load in the Pulmonary Compartment of Critically Ill COVID-19 Patients Correlates with Viral Serum Load and Fatal Outcomes.
    Ynga-Durand M; Maaß H; Milošević M; Krstanović F; Pribanić Matešić M; Jonjić S; Protić A; Brizić I; Šustić A; Čičin-Šain L
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assay.
    Taffertshofer K; Walter M; Mackeben P; Kraemer J; Potapov S; Jochum S
    Front Immunol; 2022; 13():1002576. PubMed ID: 36532081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response.
    Masiá M; Telenti G; Fernández M; García JA; Agulló V; Padilla S; García-Abellán J; Guillén L; Mascarell P; Asenjo JC; Gutiérrez F
    Open Forum Infect Dis; 2021 Feb; 8(2):ofab005. PubMed ID: 33614814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Acute Respiratory Syndrome Coronavirus 2 Viral RNA Load Status and Antibody Distribution Among Patients and Asymptomatic Carriers in Central China.
    Yuan Y; Wang H; Zhao J; Jing N; Xu J; Li W; Ma B; Zhang J; Li G; Wang S; Li Y; Wang Y; Fan E; Li L
    Front Cell Infect Microbiol; 2021; 11():559447. PubMed ID: 33816325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.